Citigroup Inc Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$12.07 - $18.46 $162,945 - $249,210	13,500 Added 23.2%	71,700 $1.06 Million
Q3 2023 Nov 09, 2023	SELL	$18.08 - $23.45 $45,199 - $58,625	-2,500 Reduced 4.12%	58,200 $1.07 Million
Q2 2023 Aug 10, 2023	BUY	$20.98 - $31.42 $1.17 Million - $1.75 Million	55,700 Added 1114.0%	60,700 $1.31 Million
Q1 2023 May 11, 2023	SELL	$27.71 - $40.93 $1.33 Million - $1.97 Million	-48,100 Reduced 90.58%	5,000 $146,000
Q4 2022 Feb 09, 2023	SELL	$29.75 - $39.26 $612,850 - $808,756	-20,600 Reduced 27.95%	53,100 $1.96 Million
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $1.26 Million - $2.28 Million	73,700 New	73,700 $2.08 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.